Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
Sponsor: Ocuphire Pharma, Inc.
Summary
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
Official title: Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
103
Start Date
2021-04-08
Completion Date
2023-01-25
Last Updated
2026-06-08
Healthy Volunteers
Yes
Conditions
Interventions
APX3330
APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
Placebo
Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
Locations (24)
Clinical Site 9
Phoenix, Arizona, United States
Clinical Site 8
Bakersfield, California, United States
Clinical Site 5
Beverly Hills, California, United States
Clinical Site 11
Palm Desert, California, United States
Clinical Site 2
Sacramento, California, United States
Clinical Site 24
Walnut Creek, California, United States
Clinical Site 19
Miami, Florida, United States
Clinical Site 7
Winter Haven, Florida, United States
Clinical Site 6
Carmel, Indiana, United States
Clinical Site 14
Hagerstown, Maryland, United States
Clinical Site 22
Springfield, Massachusetts, United States
Clinical Site 17
Grand Blanc, Michigan, United States
Clinical Site 12
Albuquerque, New Mexico, United States
Clinical Site 15
Shirley, New York, United States
Clinical Site 20
Charlotte, North Carolina, United States
Clinical Site 1
Rapid City, South Dakota, United States
Clinical Site 18
Austin, Texas, United States
Clinical Site 16
Bellaire, Texas, United States
Clinical Site 10
Fort Worth, Texas, United States
Clinical Site 4
McAllen, Texas, United States
Clinical Site 3
San Antonio, Texas, United States
Clinical Site 23
San Antonio, Texas, United States
Clinical Site 13
Southlake, Texas, United States
Clinical Site 21
Ogden, Utah, United States